BioSpace News Archive

Medivir AB announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study with MIV-818.

111, Inc., a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, and Jianming Pharmaceutical Group, a pharmaceutical manufacturer of liver and gallbladder medications, have entered into a strategic cooperation agreement to develop an online chronic disease management platform for the hepatobiliary disease market in China.

Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline

As the first baby boomers reach their 75th birthday this year, a new study commissioned by the Canadian Medical Association estimates the cost and demand for elder care will nearly double by 2031.

Expect to initiate Phase 1/2 trials of INZ-701 for ENPP1 deficiency in the first half of the year and ABCC6 deficiency by mid-2021

Istari Oncology, Inc., a clinical-stage biotechnology company, announced the publication of “Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling” in Nature Communications.

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced that management will participate in three upcoming virtual investor conferences in April

Continued progress in OVAL Phase 3 registration enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer; high CA-125 response rates (RR) of over 50% in the total evaluable patient population with more than200 patients enrolled to date.

Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the nomination of Dominik Höchli, M.D., to the Company’s Board of Directors proposed for election at the 2021 Annual General Meeting on April 21, 2021.

Canonic Ltd., a subsidiary of Evogene Ltd., focused on the development of medical cannabis products and Tikun Olam-Cannbit Pharmaceuticals Ltd., a leading medical cannabis company, announced that they have entered into agreements for the production and distribution in Israel of Canonic’s medical cannabis products.